Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O"™Neal Comprehensive Cancer Center, University of Alabama at Birmingham, provides opinion on whether minimal residual disease (MRD) tests can be used to help guide treatment decisions.